Combigene AB (ST:COMBI) — Market Cap & Net Worth
Market Cap & Net Worth: Combigene AB (COMBI)
Combigene AB (ST:COMBI) has a market capitalization of $5.24 Million (Skr48.71 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #28272 globally and #638 in its home market, demonstrating a 6.49% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Combigene AB's stock price Skr2.46 by its total outstanding shares 19801200 (19.80 Million). Analyse COMBI cash generation efficiency to see how efficiently the company converts income to cash.
Combigene AB Market Cap History: 2015 to 2025
Combigene AB's market capitalization history from 2015 to 2025. Data shows change from $200.44 Million to $5.24 Million (-28.85% CAGR).
Index Memberships
Combigene AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.03% | #195 of 281 |
Weight: Combigene AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Combigene AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Combigene AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
15.56x
Combigene AB's market cap is 15.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $49.96 Million | $3.00 Million | -$8.96 Million | 16.65x | N/A |
| 2018 | $63.59 Million | $8.15K | -$13.15 Million | 7805.74x | N/A |
| 2019 | $45.21 Million | $14.99 Million | -$17.84 Million | 3.02x | N/A |
| 2020 | $28.32 Million | $10.83 Million | -$30.77 Million | 2.62x | N/A |
| 2021 | $24.29 Million | $84.04 Million | $20.96 Million | 0.29x | 1.16x |
| 2022 | $19.47 Million | $26.70 Million | -$6.16 Million | 0.73x | N/A |
| 2023 | $5.73 Million | $5.54 Million | -$35.66 Million | 1.03x | N/A |
| 2024 | $5.07 Million | $326.00K | -$44.88 Million | 15.56x | N/A |
Competitor Companies of COMBI by Market Capitalization
Companies near Combigene AB in the global market cap rankings as of May 4, 2026.
Key companies related to Combigene AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Combigene AB Historical Marketcap From 2015 to 2025
Between 2015 and today, Combigene AB's market cap moved from $200.44 Million to $ 5.24 Million, with a yearly change of -28.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr5.24 Million | +3.36% |
| 2024 | Skr5.07 Million | -11.52% |
| 2023 | Skr5.73 Million | -70.55% |
| 2022 | Skr19.47 Million | -19.87% |
| 2021 | Skr24.29 Million | -14.23% |
| 2020 | Skr28.32 Million | -37.35% |
| 2019 | Skr45.21 Million | -28.90% |
| 2018 | Skr63.59 Million | +27.26% |
| 2017 | Skr49.96 Million | -43.92% |
| 2016 | Skr89.09 Million | -55.55% |
| 2015 | Skr200.44 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Combigene AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.24 Million USD |
| MoneyControl | $5.24 Million USD |
| MarketWatch | $5.24 Million USD |
| marketcap.company | $5.24 Million USD |
| Reuters | $5.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Combigene AB
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The… Read more